Analyst Vincent Andrews of Morgan Stanley maintained a Hold rating on Chemours Company, with a price target of $15.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vincent Andrews has given his Hold rating due to a combination of factors that reflect the current and projected financial performance of Chemours Company. The earnings per share (EPS) estimates for the upcoming years have been adjusted downward, indicating a less optimistic outlook compared to previous forecasts and consensus estimates. This adjustment suggests that the company’s profitability might face challenges in the near term.
Additionally, the EBITDA forecasts have also been revised, with some reductions in expected figures for 2025 and 2026, reflecting potential operational hurdles. The adjustments in TiO2 volumes and pricing forecasts, along with changes in feedstock pricing and foreign exchange rates, further contribute to the cautious stance. These factors combined suggest a balanced view, leading to a Hold rating, as the company navigates through these financial and market conditions.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CC in relation to earlier this year.